bi 853520
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2011 (NCT01335269)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Focal adhesion kinase 1INHIBITOR
PTK2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544961 ↗
Also known as
- bi 853520
- bi-853520
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06166836 | Phase 1/Phase 2 (Phase 2) | Oct 12, 2022 | InventisBio Inc., InxMed (Shanghai) Co., Ltd. |
| NCT01905111 | Phase 1 | Jul 1, 2013 | Boehringer Ingelheim |
| NCT01335269 | Phase 1 | Jul 1, 2011 | Boehringer Ingelheim |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 2 | 2 | 1 | 2011 |
| InventisBio Inc. | For profit | 1 | 0 | 1 | 2022 |
| InxMed (Shanghai) Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1